National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

doxorubicin-GnRH agonist conjugate AEZS-108
A peptide agonist of the gonadotropin releasing hormone-1 receptor (GnRH-1R) that is conjugated to the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Doxorubicin-GnRH agonist conjugate AEZS-108 binds to GnRH-1Rs, which may be highly expressed on endometrial and ovarian tumor cell membrane surfaces, and is internalized. Once inside the cell, the doxorubicin moiety of this agent intercalates into DNA and inhibits the topoisomerase II activity, which may result in the inhibition of tumor cell DNA replication and tumor cell proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:doxorubicin-LHRH agonist conjugate AEZS-108
Code name:AEZS-108



Previous:doxercalciferol, doxifluridine, DOXIL, doxorubicin hydrochloride, doxorubicin prodrug INNO-206
Next:doxorubicin-HPMA conjugate, doxorubicin-magnetic targeted carrier complex, doxycycline, dronabinol, droperidol

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov